For the quarter ending 2025-09-30, ALT made $5K in revenue. -$18,991K in net income. Net profit margin of -379820.00%.
| Income Statement | 2025-09-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenues | 5 | 5 | 5* | 5 |
| Research and development | 14,960 | 15,827 | 22,817* | 19,803 |
| General and administrative | 5,904 | 5,993 | 6,059* | 4,969 |
| Total operating expenses | 20,864 | 21,820 | 28,876* | 24,772 |
| Loss from operations | -20,859 | -21,815 | -28,871* | -24,767 |
| Interest expense | 495 | 1 | -9* | 6 |
| Interest income | 2,426 | 1,545 | 2,344* | 1,910 |
| Other income (expense), net | -86 | 15 | -6* | 18 |
| Total other income (expense), net | 1,845 | 1,559 | 2,347* | 1,922 |
| Net loss before income taxes | -19,014 | -20,256 | - | - |
| Income tax expense (benefit) | - | -681 | - | - |
| Net loss | -19,014 | -19,575 | -26,524* | -22,845 |
| Other comprehensive income - unrealized loss (gain) on short-term investments | 23 | -30 | -1,010* | 347 |
| Comprehensive loss | -18,991 | -19,605 | -27,534 | -22,498 |
| Basic EPS | -0.21 | -0.26 | -0.388 | -0.32 |
| Diluted EPS | -0.21 | -0.26 | -0.388 | -0.32 |
| Basic Average Shares | 89,418,028 | 75,547,746 | 70,922,011 | 71,084,787 |
| Diluted Average Shares | 89,418,028 | 75,547,746 | 70,922,011 | 71,084,787 |
Altimmune, Inc. (ALT)
Altimmune, Inc. (ALT)